Shandong Dongyue Organosilicon Mat (300821) fair value: what the stock is really worth
As of Oct 8, 2026: fair value of Shandong Dongyue Organosilicon Mat ¥6.32, price ¥14.29, upside -55.8%, quality 56 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.
How to read this chart
60‑month range ¥5.86 – ¥30.33 · fair‑value band ¥4.84 – ¥8.34 · the ¥14.29 price screens above the ¥6.32 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 29, 2026.
Follow Shandong Dongyue Organosilicon Mat in your weekly email
Every Wednesday you see whether Shandong Dongyue Organosilicon Mat is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shandong Dongyue Organosilicon Materials Co., Ltd. engages in the research and development, production, and sale of silicon materials in China. It offers monomers, intermediates, silicone rubbers, silicone oils, silicone resins; and fumed silicas; deep-processing products.
Show more
Shandong Dongyue Organosilicon Materials Co., Ltd. engages in the research and development, production, and sale of silicon materials in China. It offers monomers, intermediates, silicone rubbers, silicone oils, silicone resins; and fumed silicas; deep-processing products. The company exports its products to the United Arab Emirates, the United States, Belgium, India, South Korea, and internationally. Shandong Dongyue Organosilicon Materials Co., Ltd. was founded in 2006 and is headquartered in Zibo, China.
Stock analysis
Shandong Dongyue Organosilicon Mat (300821) currently trades at ¥14.29, while our model-based Fair Value estimate is ¥6.32, 55.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥3.49 per share, and 0 of the 13 models we run sit above the ¥14.29 price.
Bear case: the Asset-Based group reads lowest at ¥2.75, and 13 of the 13 models stay below the price. Evidence for this calculation is medium.
Scenario range: ¥4.84 (bear) to ¥8.34 (bull), the price of ¥14.29 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Basic Materials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Shandong Dongyue Organosilicon Mat reported revenue of 3.8B CNY in FY2025 versus 4.3B CNY in FY2021, a compound −3.4%/yr. Reported net income was −19.3M CNY in FY2025.
Key figures
Market cap 17.1B CNY (≈ $2.6B) · P/E ratio 47.6 · P/S ratio 4.25 · EPS (TTM) ¥0.3000 · Dividend yield 0.1% · Net margin −0.5% · Return on equity 7.1% · Return on assets (EBIT) 5.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high and 65% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −39% fair-value upside, at −56%, 300821 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥0.2100 to ¥5.37). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ¥4.84Fair Value ¥6.32Bull ¥8.34
Price ¥14.29 · Upside -55.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.2163 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−26.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−17.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.5%
Start year 2020 (pandemic). Over 10 years: +10.0% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
11.9% (2020) → −0.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+39.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +37.4% a year for the price.
Compare Shandong Dongyue Organosilicon Mat with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 714 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside−55.8% · Below median
Profitability
Return on equity (TTM)7.1% · Above median
Return on assets4.2% · Above median
Net margin (TTM)8.9% · Above median
Operating margin (TTM)18.6% · Top 25%
Growth and dividend
Revenue growth25.2% · Above median
Dividend yield (TTM)0.1% · Bottom 25%
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
P/E (TTM)47.6× · Priciest 25%
P/B3.48× · Priciest 25%
P/S (TTM)4.18× · Priciest 25%
P/FCF87.8× · Priciest 25%
EV/EBITDA19.8× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 59
PAST (return on equity)29· sector 26
HEALTH (low debt)100· sector 95
DIVIDEND (yield)3· sector 28
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shandong Dongyue Organosilicon Mat Fair Value". https://www.fairvalue-calculator.com/stock/300821
Frequently asked questions
Is Shandong Dongyue Organosilicon Mat (300821) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of ¥6.32 versus a price of ¥14.29, about −56% upside (overvalued).
What is the fair value of 300821?
Our model-based fair value for Shandong Dongyue Organosilicon Mat is ¥6.32 (as of Sep 29, 2026), built from audited fundamentals. The current price: ¥14.29.
What is the quality score of 300821?
Shandong Dongyue Organosilicon Mat has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shandong Dongyue Organosilicon Mat (300821)?
Our model-based price target is the fair value of ¥6.32 (as of Sep 29, 2026) from 13 valuation models. Cautious scenario ¥4.84, optimistic scenario ¥8.34. It is a calculation from audited fundamentals, not an analyst target.
What is the Shandong Dongyue Organosilicon Mat stock forecast for 2026?
Our models put fair value at ¥6.32, about −56% upside versus a price of ¥14.29 (overvalued). Cautious scenario ¥4.84, optimistic scenario ¥8.34. The calculation is refreshed regularly with new filings.
What is the revenue of Shandong Dongyue Organosilicon Mat (300821)?
Shandong Dongyue Organosilicon Mat reported trailing-twelve-month revenue of about 4.1B CNY (latest available figure, as of Sep 29, 2026).
Does Shandong Dongyue Organosilicon Mat pay a dividend?
Shandong Dongyue Organosilicon Mat currently shows a dividend yield of about 0.14% relative to its recent price (as of Sep 29, 2026).
What growth is priced into Shandong Dongyue Organosilicon Mat (300821)?
For today's price to be fair in a discounted-cash-flow model, Shandong Dongyue Organosilicon Mat would have to grow free cash flow by +39.7 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.5 % per year. As of Sep 29, 2026.
What discount rate (WACC) does the fair value of 300821 use?
Our models discount Shandong Dongyue Organosilicon Mat at 10.5 %: a base by market capitalisation (mid), damped by beta 1.04, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shandong Dongyue Organosilicon Mat that is +39.7 % per year a year over ten years, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has Shandong Dongyue Organosilicon Mat (300821) delivered so far?
Over the past 5 years revenue at Shandong Dongyue Organosilicon Mat grew +8.5 % a year. The price currently implies +39.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shandong Dongyue Organosilicon Mat (300821) growing?
The median revenue growth in the sector is +9.1 % a year. That is the yardstick for the growth priced into Shandong Dongyue Organosilicon Mat (+39.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shandong Dongyue Organosilicon Mat (300821)?
The free-cash-flow yield on the price is 1.14 %: that much free cash flow Shandong Dongyue Organosilicon Mat produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shandong Dongyue Organosilicon Mat (300821)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shandong Dongyue Organosilicon Mat it is ¥6.32 per share (as of Sep 29, 2026), against a price of ¥14.29. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Shandong Dongyue Organosilicon Mat stock overvalued or undervalued in 2026?
As of Sep 29, 2026, 300821 trades above its calculated fair value: price ¥14.29, fair value ¥6.32, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300821?
No. The price is what the market pays today (¥14.29); the fair value is what the company's own numbers justify (¥6.32). For Shandong Dongyue Organosilicon Mat the two are ¥7.97 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shandong Dongyue Organosilicon Mat worth?
The market values Shandong Dongyue Organosilicon Mat at about 17.1B CNY (market capitalisation, as of Sep 29, 2026). Per share that is ¥14.29; our models calculate a fair value of ¥6.32 per share.
What do the bullish and bearish scenarios say about 300821?
Our models span a range for Shandong Dongyue Organosilicon Mat: cautious scenario ¥4.84, base ¥6.32, optimistic ¥8.34 per share (as of Sep 29, 2026, price ¥14.29). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 300821?
Shandong Dongyue Organosilicon Mat trades at a price-to-earnings ratio of 47.6 (as of Sep 29, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥6.32 is built from several models across several years. Other multiples: P/B 3.5, P/S 4.2, EV/EBITDA 19.8.
How solid is the balance sheet of Shandong Dongyue Organosilicon Mat (300821)?
Balance-sheet figures for Shandong Dongyue Organosilicon Mat (as of Sep 29, 2026): return on equity 7.1%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 300821 from its 52-week high?
Shandong Dongyue Organosilicon Mat trades at ¥14.29, about 53% below its 52-week high of ¥30.33 and 65% above the low of ¥8.66 (as of Oct 8, 2026). Distance from the high says nothing about value: that is what the fair value of ¥6.32 is for.
Which stocks are comparable to Shandong Dongyue Organosilicon Mat?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shandong Dongyue Organosilicon Mat stock attractive at the current price?
The data as of Sep 29, 2026: price ¥14.29, calculated fair value ¥6.32 (−56%), Quality Score 56/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300821 calculated?
We run Shandong Dongyue Organosilicon Mat through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥6.32, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Shandong Dongyue Organosilicon Mat itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shandong Dongyue Organosilicon Mat (300821)?
The closing price on Oct 8, 2026 was ¥14.29. Our model-based fair value is ¥6.32, about −56% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shandong Dongyue Organosilicon Mat right now?
The price sits above even our optimistic bull case (¥8.34). The favourable scenario is already priced in. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Shandong Dongyue Organosilicon Mat
How large is the market capitalisation of Shandong Dongyue Organosilicon Mat (300821)?
The market capitalisation of Shandong Dongyue Organosilicon Mat is 17.1B CNY (≈ $2.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shandong Dongyue Organosilicon Mat (300821)?
The price-to-sales ratio of Shandong Dongyue Organosilicon Mat is 4.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shandong Dongyue Organosilicon Mat (300821)?
Earnings per share at Shandong Dongyue Organosilicon Mat are ¥0.3000 (price ÷ EPS = P/E 47.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shandong Dongyue Organosilicon Mat (300821)?
The dividend yield of Shandong Dongyue Organosilicon Mat is 0.1% (payout 6.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shandong Dongyue Organosilicon Mat (300821)?
The net margin of Shandong Dongyue Organosilicon Mat is −0.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shandong Dongyue Organosilicon Mat (300821)?
The return on equity (ROE) of Shandong Dongyue Organosilicon Mat is 7.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shandong Dongyue Organosilicon Mat (300821)?
On an EBIT basis the return on assets of Shandong Dongyue Organosilicon Mat is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shandong Dongyue Organosilicon Mat (300821)?
The operating margin of Shandong Dongyue Organosilicon Mat is 18.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shandong Dongyue Organosilicon Mat (300821)?
Revenue at Shandong Dongyue Organosilicon Mat is growing +25.2% versus a year earlier (3y avg −17.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shandong Dongyue Organosilicon Mat (300821)?
Earnings per share at Shandong Dongyue Organosilicon Mat are growing +32.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Shandong Dongyue Organosilicon Mat (300821) hold?
Shandong Dongyue Organosilicon Mat holds more cash than debt, 981M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Shandong Dongyue Organosilicon Mat in the live analysis
One click puts Shandong Dongyue Organosilicon Mat on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
